Results 1 to 10 of about 57,012 (205)

Development and validation of BCG vaccine-induced novel granulomatous liver injury preclinical animal model. [PDF]

open access: diamondAnimal Model Exp Med
Sharma S   +8 more
europepmc   +3 more sources

P-1398. BCG Vaccine Prevents Primary Tuberculosis in Newborns and School Children [PDF]

open access: goldOpen Forum Infect Dis
Naomi Aronson   +6 more
europepmc   +2 more sources

Natural variation in immune responses to neonatal mycobacterium bovis bacillus calmette-guerin (BCG) vaccination in a cohort of Gambian infants [PDF]

open access: yes, 2008
Background There is a need for new vaccines for tuberculosis (TB) that protect against adult pulmonary disease in regions where BCG is not effective.
A Lalvani   +46 more
core   +16 more sources

Reference genome and comparative genome analysis for the WHO reference strain for Mycobacterium bovis BCG Danish, the present tuberculosis vaccine [PDF]

open access: yes, 2019
Background: Mycobacterium bovis bacillus Calmette-Guerin (M. bovis BCG) is the only vaccine available against tuberculosis (TB). In an effort to standardize the vaccine production, three substrains, i.e. BCG Danish 1331, Tokyo 172-1 and Russia BCG-1 were
Borgers, Katlyn   +9 more
core   +2 more sources

B Cells Regulate Neutrophilia during Mycobacterium tuberculosis Infection and BCG Vaccination by Modulating the Interleukin-17 Response [PDF]

open access: yes, 2013
We have previously demonstrated that B cells can shape the immune response to Mycobacterium tuberculosis, including the level of neutrophil infiltration and granulomatous inflammation at the site of infection. The present study examined the mechanisms by
A Casadevall   +74 more
core   +3 more sources

Mucosal delivery of tuberculosis vaccines: a review of current approaches and challenges. [PDF]

open access: yes, 2019
Introduction: Tuberculosis (TB) remains a major health threat and it is now clear that the current vaccine, BCG, is unable to arrest the global TB epidemic. A new vaccine is needed to either replace or boost BCG so that a better level of protection could
Barclay WR   +8 more
core   +1 more source

BCG Vaccines

open access: yesMicrobiology Spectrum, 2014
ABSTRACT BCG is the collective name for a family of live attenuated strains of Mycobacterium bovis that are currently used as the only vaccine against tuberculosis (TB). There are two major reasons for studying the genome of these organisms: (i) Because they are attenuated, BCG vaccines provide a window ...
Vanessa, Tran, Jun, Liu, Marcel A, Behr
openaire   +2 more sources

Screening vaccine formulations for biological activity using fresh human whole blood. [PDF]

open access: yes, 2014
Understanding the relevant biological activity of any pharmaceutical formulation destined for human use is crucial. For vaccine-based formulations, activity must reflect the expected immune response, while for non-vaccine therapeutic agents, such as ...
Aboutorabian, Sepideh   +9 more
core   +1 more source

PO and ID BCG vaccination in humans induce distinct mucosal and systemic immune responses and CD4(+) T cell transcriptomal molecular signatures. [PDF]

open access: yes, 2017
Protective efficacy of Bacillus Calmette-Guérin (BCG) may be affected by the methods and routes of vaccine administration. We have studied the safety and immunogenicity of oral (PO) and/or intradermal (ID) administration of BCG in healthy human subjects.
Andersen, P. L.   +11 more
core   +1 more source

The impact of HIV exposure and maternal Mycobacterium tuberculosis infection on infant immune responses to bacille Calmette-Guérin vaccination. [PDF]

open access: yes, 2015
OBJECTIVE: The objective of this study is to assess the effect of maternal HIV and Mycobacterium tuberculosis (Mtb) infection on cellular responses to bacille Calmette-Guérin (BCG) immunization. DESIGN: A mother-infant cohort study.
Adegnika   +45 more
core   +2 more sources

Home - About - Disclaimer - Privacy